Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%–30% of breast cancer patients. Anti-HER2 therapies have changed the aggressive course of HER2+ breast cancer. In spite of the therapeutic benefits, their cardiotoxicities are major concerns, especially when used concurrently...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2017-09-01
|
| Series: | Genes and Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304217300466 |
| _version_ | 1797716557638402048 |
|---|---|
| author | Ibrahim Sadek Mark Keaton Nita J. Maihle Shou-Ching Tang |
| author_facet | Ibrahim Sadek Mark Keaton Nita J. Maihle Shou-Ching Tang |
| author_sort | Ibrahim Sadek |
| collection | DOAJ |
| description | The human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%–30% of breast cancer patients. Anti-HER2 therapies have changed the aggressive course of HER2+ breast cancer. In spite of the therapeutic benefits, their cardiotoxicities are major concerns, especially when used concurrently with anthracyclines.
Here we present an elderly patient with relapsed HER2+ breast cancer. Her presentation for relapsed disease was unusual for the physical finding as well as the history of trastuzumab-induced severe cardiotoxicity while requiring additional anti-HER2 therapy. She received neoadjuvant anti-HER2 treatment for stage III breast caner. Due to severe reduction of cardiac ejection fraction (EF), she only received five doses of adjuvant transtuzumab. Unfortunately her disease relapsed one year later with chest wall lesions and a persistent low EF. We treated the patient with lapatinib combined with capecitabine which resulted rapid resolution of her chest wall lesion. More importantly, the patient had one year of disease control without deterioration in her ejection fraction. We discussed the management of recurrent HER2+ breast cancer with chest wall disease and the choice of anti-HER2 therapy in patients with a history of transtuzumab-induced cardiac dysfunction. |
| first_indexed | 2024-03-12T08:23:14Z |
| format | Article |
| id | doaj.art-f011c4d865d64d56966aa1a678d33b77 |
| institution | Directory Open Access Journal |
| issn | 2352-3042 |
| language | English |
| last_indexed | 2024-03-12T08:23:14Z |
| publishDate | 2017-09-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Genes and Diseases |
| spelling | doaj.art-f011c4d865d64d56966aa1a678d33b772023-09-02T18:19:41ZengKeAi Communications Co., Ltd.Genes and Diseases2352-30422017-09-014315916210.1016/j.gendis.2017.07.007Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicityIbrahim Sadek0Mark Keaton1Nita J. Maihle2Shou-Ching Tang3Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USAGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USAGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USAGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USAThe human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%–30% of breast cancer patients. Anti-HER2 therapies have changed the aggressive course of HER2+ breast cancer. In spite of the therapeutic benefits, their cardiotoxicities are major concerns, especially when used concurrently with anthracyclines. Here we present an elderly patient with relapsed HER2+ breast cancer. Her presentation for relapsed disease was unusual for the physical finding as well as the history of trastuzumab-induced severe cardiotoxicity while requiring additional anti-HER2 therapy. She received neoadjuvant anti-HER2 treatment for stage III breast caner. Due to severe reduction of cardiac ejection fraction (EF), she only received five doses of adjuvant transtuzumab. Unfortunately her disease relapsed one year later with chest wall lesions and a persistent low EF. We treated the patient with lapatinib combined with capecitabine which resulted rapid resolution of her chest wall lesion. More importantly, the patient had one year of disease control without deterioration in her ejection fraction. We discussed the management of recurrent HER2+ breast cancer with chest wall disease and the choice of anti-HER2 therapy in patients with a history of transtuzumab-induced cardiac dysfunction.http://www.sciencedirect.com/science/article/pii/S2352304217300466Diagnosis and managementHER2 positive breast cancerLapatinibTrastuzumab-induced cardiac toxicityUnusual presentation |
| spellingShingle | Ibrahim Sadek Mark Keaton Nita J. Maihle Shou-Ching Tang Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity Genes and Diseases Diagnosis and management HER2 positive breast cancer Lapatinib Trastuzumab-induced cardiac toxicity Unusual presentation |
| title | Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity |
| title_full | Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity |
| title_fullStr | Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity |
| title_full_unstemmed | Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity |
| title_short | Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity |
| title_sort | anti her 2 therapy following severe trastuzumab induced cardiac toxicity |
| topic | Diagnosis and management HER2 positive breast cancer Lapatinib Trastuzumab-induced cardiac toxicity Unusual presentation |
| url | http://www.sciencedirect.com/science/article/pii/S2352304217300466 |
| work_keys_str_mv | AT ibrahimsadek antiher2therapyfollowingseveretrastuzumabinducedcardiactoxicity AT markkeaton antiher2therapyfollowingseveretrastuzumabinducedcardiactoxicity AT nitajmaihle antiher2therapyfollowingseveretrastuzumabinducedcardiactoxicity AT shouchingtang antiher2therapyfollowingseveretrastuzumabinducedcardiactoxicity |